ULTOMIRIS (ravulizumab-cwvz) is the first and only long-acting C5 complement inhibitor that offers patients with aquaporin-4 (AQP4) antibody-positive (Ab+) neuromyelitis optica spectrum disorder (NMOSD) the potential to live relapse-free.
In comparison to other therapeutic options, ravulizumab stands out as a symbol of pioneering progress and efficacy, surpassing competitors with its remarkable reduction in relapse risk and promising outcomes for patients with NMOSD.
In the tapestry of autoimmune diseases, NMOSD emerges as a formidable adversary, wreaking havoc on the central nervous system (CNS). Amidst the arsenal of approved therapies, the quest for the mos...
